Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 1637-1641, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, D. R.
Right arrow Articles by Zoccoli, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, D. R.
Right arrow Articles by Zoccoli, M. A.

Clinical Chemistry, Vol 32, 1637-1641, Copyright © 1986 by American Association for Clinical Chemistry

CEDIA, a new homogeneous immunoassay system

DR Henderson, SB Friedman, JD Harris, WB Manning and MA Zoccoli

Genetic engineering of beta-galactosidase (EC 3.2.1.23) has led to the development of a new homogeneous assay system, CEDIA. The Z gene of the lac operon of Escherichia coli encodes a large enzymatically inactive polypeptide that spontaneously aggregates and folds to form active beta- galactosidase. Using recombinant DNA techniques, we have been able to engineer beta-galactosidase protein into a large polypeptide (an enzyme acceptor, EA) and a small polypeptide (an enzyme donor, ED). The EAs and EDs are both enzymatically inactive, but spontaneously associate to form enzymatically active tetramers. In the assay, hapten or analyte is attached to an ED, and an analyte-specific antibody is used to inhibit the spontaneous assembly of active enzyme. Analyte in a patient's serum competes with the analyte in the analyte-ED conjugate for antibody, modulating the amount of beta-galactosidase formed. The signal generated by enzyme substrates is directly proportional to the analyte concentrations in the patient's serum. We describe quick (5-15 min) colorimetric tests for digoxin, requiring no serum pretreatments or predilutions and suitable for use with centrifugal and random-access analyzers.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Clin. Nutr.Home page
V. W Persky, M. E Turyk, L. Wang, S. Freels, R. Chatterton Jr, S. Barnes, J. Erdman Jr, D. W Sepkovic, H L. Bradlow, and S. Potter
Effect of soy protein on endogenous hormones in postmenopausal women
Am. J. Clinical Nutrition, January 1, 2002; 75(1): 145 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
R. Arai, H. Ueda, K. Tsumoto, W. C. Mahoney, I. Kumagai, and T. Nagamune
Fluorolabeling of antibody variable domains with green fluorescent protein variants: application to an energy transfer-based homogeneous immunoassay
Protein Eng. Des. Sel., May 1, 2000; 13(5): 369 - 376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Benito, J. X. Feliu, and A. Villaverde
beta -Galactosidase Enzymatic Activity as a Molecular Probe to Detect Specific Antibodies
J. Biol. Chem., August 30, 1996; 271(35): 21251 - 21256.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.